TScan Therapeutics, Inc.
TCRX
$1.27
-$0.11-7.97%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 4.42M | 2.82M | 9.36M | 12.20M | 14.81M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.42M | 2.82M | 9.36M | 12.20M | 14.81M |
| Cost of Revenue | 9.78M | 4.85M | 15.13M | 11.60M | 5.95M |
| Gross Profit | -5.36M | -2.03M | -5.76M | 596.00K | 8.86M |
| SG&A Expenses | 31.84M | 30.29M | 28.43M | 26.91M | 25.67M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 144.12M | 137.64M | 128.83M | 123.79M | 116.90M |
| Operating Income | -139.70M | -134.82M | -119.47M | -111.59M | -102.09M |
| Income Before Tax | -131.48M | -127.50M | -111.30M | -104.41M | -96.80M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -131.48 | -127.50 | -111.30 | -104.41 | -96.80 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -131.48M | -127.50M | -111.30M | -104.41M | -96.80M |
| EBIT | -139.70M | -134.82M | -119.47M | -111.59M | -102.09M |
| EBITDA | -136.17M | -130.71M | -114.79M | -106.66M | -96.97M |
| EPS Basic | -2.05 | -2.42 | -2.20 | -2.12 | -2.03 |
| Normalized Basic EPS | -1.27 | -1.50 | -1.37 | -1.32 | -1.27 |
| EPS Diluted | -2.05 | -2.42 | -2.20 | -2.12 | -2.03 |
| Normalized Diluted EPS | -1.27 | -1.50 | -1.37 | -1.32 | -1.27 |
| Average Basic Shares Outstanding | 292.56M | 210.78M | 202.02M | 196.49M | 190.77M |
| Average Diluted Shares Outstanding | 292.56M | 210.78M | 202.02M | 196.49M | 190.77M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |